Comparison · NCT02301143-sae
Nab-Paclitaxel Plus Gemcitabine (Induction Period) vs Nab-Paclitaxel Plus Gemcitabine (Overall): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nab-Paclitaxel Plus Gemcitabine (Induction Period) vs Nab-Paclitaxel Plus Gemcitabine (Overall): serious adverse events. Trial comparisons, record NCT02301143-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02301143-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.358 | 0.274 | 0.453 | wilson | |
| Risk in group 2 | 0.368 | 0.282 | 0.463 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00943 | -0.137 | 0.118 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.974 | 0.682 | 1.39 | log | |
| Odds ratio, group 1 over group 2 | 0.96 | 0.548 | 1.68 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Nab-Paclitaxel Plus Gemcitabine (Induction Period) than on Nab-Paclitaxel Plus Gemcitabine (Overall) | 106 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nab-Paclitaxel Plus Gemcitabine (Induction Period) | nab-Paclitaxel 125 mg/m\^2 intravenous (IV) infusion administered over approximately 30-45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m\^2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle. | 38 | 106 | EG000 |
| Group 2 | Nab-Paclitaxel Plus Gemcitabine (Overall) | nab-Paclitaxel 125 mg/m\^2 intravenous (IV) infusion administered over approximately 30-45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m\^2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle. Overall includes nab-Paclitaxel plus Gemcitabine treatment cycles during the Induction Period, as well as the subset of participants who continued the regimen during the Investigator Choice Period. | 39 | 106 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Day 1 of study drug up to end of the study; up to 31.3 months
Source ClinicalTrials.gov
Trial
- Title
- Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
- NCT number
- NCT02301143
- Phases
- PHASE2
- Conditions
- Pancreatic Neoplasms
- Interventions
- nab-Paclitaxel, Gemcitabine, Chemoradiation, Capecitabine, Surgery
- Lead sponsor
- Celgene
- Results first posted
- 2019-01-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02301143?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02301143-sae